Recent Insider Transactions • Jun 23
CEO & Executive Director recently sold €13m worth of stock On the 16th of June, Javier Rodriguez sold around 69k shares on-market at roughly €180 per share. This transaction amounted to 8.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Javier's only on-market trade for the last 12 months. Recent Insider Transactions • May 13
CFO & Treasurer recently sold €8.4m worth of stock On the 7th of May, Joel Ackerman sold around 51k shares on-market at roughly €163 per share. This transaction amounted to 34% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Joel's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • May 12
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to €170, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 16x in the Healthcare industry in Europe. Total returns to shareholders of 35% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €121 per share. Reported Earnings • May 06
First quarter 2026 earnings released: EPS: US$2.93 (vs US$2.05 in 1Q 2025) First quarter 2026 results: EPS: US$2.93 (up from US$2.05 in 1Q 2025). Revenue: US$3.42b (up 6.0% from 1Q 2025). Net income: US$197.5m (up 21% from 1Q 2025). Profit margin: 5.8% (up from 5.1% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Healthcare industry in Europe. Buy Or Sell Opportunity • May 06
Now 45% overvalued after recent price rise Over the last 90 days, the stock has risen 30% to €160. The fair value is estimated to be €111, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 4.7% per annum. Earnings are also forecast to grow by 7.7% per annum over the same time period. Announcement • Apr 23
DaVita Inc., Annual General Meeting, Jun 04, 2026 DaVita Inc., Annual General Meeting, Jun 04, 2026. Announcement • Apr 21
DaVita Inc. to Report Q1, 2026 Results on May 05, 2026 DaVita Inc. announced that they will report Q1, 2026 results After-Market on May 05, 2026 Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to €119, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 17x in the Healthcare industry in Europe. Reported Earnings • Feb 03
Full year 2025 earnings released: EPS: US$9.72 (vs US$11.02 in FY 2024) Full year 2025 results: EPS: US$9.72 (down from US$11.02 in FY 2024). Revenue: US$13.6b (up 6.5% from FY 2024). Net income: US$721.8m (down 23% from FY 2024). Profit margin: 5.3% (down from 7.3% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Healthcare industry in Europe. Announcement • Jan 21
DaVita Inc. to Report Q4, 2025 Results on Feb 02, 2026 DaVita Inc. announced that they will report Q4, 2025 results After-Market on Feb 02, 2026 New Risk • Dec 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (5.6% average weekly change). Announcement • Dec 11
Davita Inc. Appoints Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, Effective December 11, 2025 DaVita Inc. has appointed Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, effective December 11, 2025. Hendrickson, who joined DaVita in 2013, has built a reputation for building and growing strong teams across the healthcare provider, medical device, and pharmaceutical sectors. She earned her undergraduate degree from California Polytechnic State University, San Luis Obispo and an MBA from the Paul Merage School of Business at the University of California, Irvine. As Chief Strategy Officer, Phillips will expand his leadership role to oversee both DaVita Venture Group and the corporate strategy function. During his tenure, he has led strategic initiatives and investments that support patients across all stages of kidney health. Phillips has a background in healthcare strategy and experience that spans services, pharmaceuticals and medical devices. He holds a bachelor's degree from Lafayette College and an MBA from the University of Virginia's Darden School of Business. These appointments underscore DaVita's commitment to bold, visionary leadership in healthcare. As care continues to evolve—driven by advancing technologies and changing patient needs—our leaders are focused on shaping solutions that improve outcomes, strengthen communities, and set new standards for care. Together, they will help drive innovation and foster a culture where both patients and teammates can thrive. Announcement • Nov 04
DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025 DaVita announced that it is unveiling six new studies at the American Society of Nephrology's (ASN) Kidney Week 2025, taking place Nov. 5-9 in Houston, Texas. These studies reflect DaVita's ongoing commitment to advancing kidney treatment through data-driven insights -- spanning dialysis treatments, including emerging pathways to middle molecule clearance, and expanding access to transplantation, end-of-life care and more. As DaVita celebrates 25 years of clinical innovation, its research continues to push the boundaries of what's possible in improving outcomes and quality of life for patients with kidney disease. DaVita will showcase research at the upcoming event, highlighted by an oral presentation from Dr. Steven Brunelli titled "GLP-1 Receptor Agonist Use Associated with Improvement in Hospitalization Rates in Patients with ESKD." This study, which explores how GLP-1 receptor agonists may reduce hospitalizations among patients with end-stage kidney disease, was authored by Rizwan Qazi (Kidney Specialists of Southern Nevada), Terrence Bjordahl (University of Utah, Department of Medicine, Division of Nephrology), and DaVita researchersSteph Karpinski, Scott Sibbel, Eric Weinhandl, Francesca Tentori and Steven Brunelli. The project originated from DaVita's innovative program inviting independent medical directors to submit research ideas, ensuring studies reflect real-world perspectives from prescribing nephrologists. This year, poster presentations from DaVita will include: Associations of Comorbid Conditions with Outcomes in Patients Initiating Home Dialysis; Authors: Eric Weinhandl, Mark Shapiro, Michelle Cassin, Mihran Naljayan; Positive Clinical Outcomes for In-Center Nocturnal Patients Observed in Certain Subgroups; Authors: Claire Ryan, Scott Sibbel, Mark Shapiro, Michelle Cass in Mihran Naljaya, Eric Weinhandl, Steven M. Brunelli. In addition to the research presentations, DaVita is spotlighting a nephrology community focus on middle-molecule clearance, a frontier in dialysis treatment innovation. While conventional hemodialysis effectively removes small molecules, larger middle molecules -- linked to chronic inflammation and cardiovascular complications -- often remain. DaVita is actively exploring advanced therapies and technologies to help address this challenge and improve long-term outcomes for dialysis patients. Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: US$2.09 (vs US$2.56 in 3Q 2024) Third quarter 2025 results: EPS: US$2.09 (down from US$2.56 in 3Q 2024). Revenue: US$3.42b (up 4.8% from 3Q 2024). Net income: US$150.3m (down 30% from 3Q 2024). Profit margin: 4.4% (down from 6.6% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Healthcare industry in Europe. Announcement • Oct 21
Davita Announces the Launch of Two Groundbreaking Initiatives DaVita announced the launch of two groundbreaking initiatives aimed to deepen the medical community's understanding of middle-molecule removal and its potential to improve outcomes for patients with kidney failure. Research shows that when waste particles with larger molecular weight build up in the blood, patients may present higher inflammation and weakened immune response, which can contribute to adverse clinical outcomes. While benefits of middle-mole molecule removal have been studied internationally, there is limited evidence in the U.S. patient population. DaVita's new initiatives will be the first to generate U.S.-based data to inform care standards and improve outcomes for patients with kidney success. To better understand the role of middle-molecule clearance and impact on patients' outcomes, DaVita will launch two complementary evaluations that will explore the use of medium cut-off dialyzers in dialysis treatments. MODEL is a quality improvement initiative that will examine the survival of U.S. patients treated with medium cut-off dialyzer. The MEMOIRS survey is a prospective cohort study of patient-reported outcomes, compared the experiences of patients treated with medium cut- off versus high-flux dialyzers. Together, the MODEL and MEMOIRS initiatives will include approximately 9,000 adults living with end stage kidney disease (ESKD) over the next two years. These large-scale reviews will investigate whether the removal of hard-to-clear waste molecules during dialysis can lead to measurable improvements in both clinical outcomes and patients' quality of life. Announcement • Oct 14
DaVita Inc. to Report Q3, 2025 Results on Oct 29, 2025 DaVita Inc. announced that they will report Q3, 2025 results After-Market on Oct 29, 2025 Announcement • Sep 22
DaVita Inc.(NYSE:DVA) dropped from FTSE All-World Index (USD) DaVita Inc.(NYSE:DVA) dropped from FTSE All-World Index (USD) Buy Or Sell Opportunity • Jul 29
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 3.0% to €127. The fair value is estimated to be €105, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 4.5% per annum. Earnings are also forecast to grow by 5.3% per annum over the same time period. Announcement • Jul 18
DaVita Inc. to Report Q2, 2025 Results on Aug 05, 2025 DaVita Inc. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025 